Clinical trial
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT01043666 |
|---|---|
| Title | A Study of YM178 in Subjects With Symptoms of Overactive Bladder |
| Official title | Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urinary Bladder, Overactive |
| Intervention type | Drug |
| Interventions | YM178, Placebo, tolterodine ER |
| Enrollment | 1,126 |
| Start date | Dec 21, 2009 |
| Primary completion | Sep 16, 2011 |
| Completion | Sep 16, 2011 |
| First posted | Jan 7, 2010 |
| Last update posted | Oct 31, 2024 |
| Countries | China, India, South Korea, Taiwan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: